Literature DB >> 8486672

Role of calcium entry and protein kinase C in the progression activity of insulin-like growth factor-I in Balb/c 3T3 cells.

I Kojima1, H Mogami, H Shibata, E Ogata.   

Abstract

We previously reported that insulin-like growth factor-I (IGF-I) stimulated calcium entry (Kojima, I., Matsunaga, H., Kurokawa, K., Ogata, E., and Nishimoto, I. (1988) J. Biol. Chem. 263, 16561-16567) and production of 1,2-diacylglycerol in IGF-responsive "primed competent" Balb/c 3T3 cells (Kojima, I., Kitaoka, M., and Ogata, E. (1990) J. Biol. Chem. 265, 16846-16850). The present study was conducted to determine a role of protein kinase C (PKC) in the progression activity of IGF-I. To monitor the activity of PKC in intact cells, we measured phosphorylation of a synthetic KRTLRR peptide, a substrate of PKC, immediately after the permeabilization of the cells with digitonin. When 1 nM IGF-I was added to primed competent cells, KRTLRR peptide phosphorylation was augmented. IGF-I induced more than 2-fold increase in KRTLRR peptide phosphorylation that was blocked by PKC19-36, a pseudosubstrate of PKC, which blocks the activity of the kinase, and Ro31-8220, an inhibitor of PKC. The phosphorylation remained elevated for up to 6 h. To assess the role of PKC in cell cycle progression, IGF-I-induced nuclear labeling was measured in the presence of Ro31-8220. Ro31-8220 reduced the rate of entrance into S phase when added in the first quarter of the G1 phase, but did not affect cell cycle progression when added at the second quarter or later. In contrast, reduction of extracellular calcium completely blocked cell cycle progression when done in the first, second, and third quarter but had no effect in the last quarter. These results indicate that IGF-I persistently activates PKC in primed competent cells, but the activation is required only for the initiation of progression. We conclude that IGF-I promotes cell cycle progression by calcium-dependent mechanisms that are largely independent of PKC.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486672

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  Intracellular calcium signals and control of cell proliferation: how many mechanisms?

Authors:  L Munaron; S Antoniotti; D Lovisolo
Journal:  J Cell Mol Med       Date:  2004 Apr-Jun       Impact factor: 5.310

2.  Cell cycle-dependent regulation of store-operated I(CRAC) and Mg2+-nucleotide-regulated MagNuM (TRPM7) currents.

Authors:  Dawn Tani; Mahealani K Monteilh-Zoller; Andrea Fleig; Reinhold Penner
Journal:  Cell Calcium       Date:  2006-10-24       Impact factor: 6.817

Review 3.  Calcium-mediated signal transduction: biology, biochemistry, and therapy.

Authors:  K Cole; E Kohn
Journal:  Cancer Metastasis Rev       Date:  1994-03       Impact factor: 9.264

4.  Rate of calcium entry determines the rapid changes in protein kinase C activity in angiotensin II-stimulated adrenal glomerulosa cells.

Authors:  I Kojima; N Kawamura; H Shibata
Journal:  Biochem J       Date:  1994-02-01       Impact factor: 3.857

5.  The neuroendocrine phenotype of gastric myofibroblasts and its loss with cancer progression.

Authors:  Silvia Balabanova; Chris Holmberg; Islay Steele; Bahram Ebrahimi; Lucille Rainbow; Ted Burdyga; Cathy McCaig; Lazso Tiszlavicz; Nantaporn Lertkowit; Olivier T Giger; Simon Oliver; Ian Prior; Rod Dimaline; Deborah Simpson; Rob Beynon; Peter Hegyi; Timothy C Wang; Graham J Dockray; Andrea Varro
Journal:  Carcinogenesis       Date:  2014-04-07       Impact factor: 4.944

6.  Differential inhibitor sensitivity between human kinases VRK1 and VRK2.

Authors:  Marta Vázquez-Cedeira; Iria Barcia-Sanjurjo; Marta Sanz-García; Ramiro Barcia; Pedro A Lazo
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

7.  Regulation of calcium-permeable TRPV2 channel by insulin in pancreatic beta-cells.

Authors:  Etsuko Hisanaga; Masahiro Nagasawa; Kohjiro Ueki; Rohit N Kulkarni; Masatomo Mori; Itaru Kojima
Journal:  Diabetes       Date:  2008-11-04       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.